Welcome to Arrien Pharmaceuticals
Arrien Pharmaceuticals is a clinical stage drug discovery company focused on developing small molecules targeting protein kinase signaling, nuclear hormone receptor and immuno-oncology/checkpoint pathway targets for treating human cancers, autoimmune and neurodegenerative diseases.
The company successfully applied its proprietary platform technology and discovered two clinical candidates and others in development:
- SLX-0528 (previously known as XT-0528/BOS-172767/ARN-6039), an orally available, selective small molecule inhibitor of ROR-γt (retinoic acid-related orphan nuclear hormone receptor gamma-t) being investigated in a Phase 1 clinical trials. The progress of ARN-6039 into Phase 1 development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. ARN-6039 was partnered with Boston Pharmaceuticals in 2017. Additional Phase 1b trials utilizing improved dosage form wad conducted on a separated enantiomers of BOS-172767. Clinical Phase 2 POC trials in psoriasis and other autoimmune indications planed for Q1 2021 was not initiated. Boston Pharmaceuticals returned ARN-6039 or BOS-172767 to Arrien Pharmaceuticals in January 2021 and the company successfully relicensed to Xenter, Inc., in June 2021. Our initial licensing of ARN-6039 to Boston Pharmaceuticals, subsequently to Xenter, Inc., and now SLX-0528, Signalexis, Inc., owns, positioned for pancreatic cancers. Despite significant delay in conducting POC trails in psoriasis, Signalexis currently in the process of submitting IND to FDA Oncology products for pancreatic cancers is an encouraging, and further validates the importance of targeting ROR-γt/IL-17 axis.
- ARN-3261, an orally available small molecule inhibitor of SIK2 (Salt Inducible Kinase 2) to be investigated in a Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors (TNBC, DLBCL & Prostate) and AML cancers. ARN-3261 (now called GRN300) licensed to Greenfire, Inc. Phase 1a/1b trials initiated in Q2 2021.
- ARN-0953, an orally available, highly selective small molecule inhibitor of the MELK (Maternal Embryonic Leucine Zipper Kinase) and FLT3/CD135 (FMS like Tyrosine Kinase 3) specific kinases. ARN-0953 currently in IND enabling studies and to be investigated in Phase 1 clinical trials for AML and other solid tumors (TNBC, GBM & Lung cancers). ARN-0953 is available for license.
- ARN-4079, an IND stage oral JAK3 selective inhibitor (now called OR-101) for dermatology indications, licensed to Ornovi, Inc., in August 2021.
Arrien Pharmaceuticals competitive and unique drug discovery and development approaches coupled with experienced scientific, clinical and business team who are expertise in multidisciplinary areas of kinase signaling, nuclear hormone receptor and checkpoint pathways and technology has been the key to company's success since its incorporation in 2011.
Our Licensed Small Molecule Oncology Programs
Our Licensed Small Molecule Autoimmune & Dermatology Programs